Globe Newswire » trang 340 » Trang Công Nghệ | Trangcongnghe.vn

Picus Security Finds 46% of Enterprise Passwords Vulnerable to Cracking — 2X Increase From 2024

Picus Security Finds 46% of Enterprise Passwords Vulnerable to Cracking — 2X Increase From 2024

Globenewswire -

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Globenewswire -

CGTN: 'Dongji Rescue': Humanity forged in blood and fire

CGTN: 'Dongji Rescue': Humanity forged in blood and fire

Globenewswire -

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Globenewswire -

The Go-No-Go (GNG) Machine is Named by DUPR, Pickleballtournaments.com and The UPA-A as the Official and Exclusive On-Site Deflection Testing Device for Professional and Amateur Tours Across the Globe

The Go-No-Go (GNG) Machine is Named by DUPR, Pickleballtournaments.com and The UPA-A as the Official and Exclusive On-Site Deflection Testing Device for Professional and Amateur Tours Across the Globe

Globenewswire -

Yachting: Five years of sustainable innovation at Yacht Club de Monaco, Rendezvous set for September 21-22

Yachting: Five years of sustainable innovation at Yacht Club de Monaco, Rendezvous set for September 21-22

Globenewswire -

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Globenewswire -

XEM THÊM TIN MỚI